ARTICLES BY THIS AUTHOR
- 6/26/2011
OMA ‘blindsided’ by crackdown on fishy OHIP billing
TORONTO | The Ontario Medical Association is reeling from the provincial government’s decision to ramp up investigations into suspicious Ontario Health Insurance Plan (OHIP) billings—a decision that is sitting well with other health-care workers and groups. - 6/23/2011
South African MDs take hospital security fears public
Doctor fatally stabbed at Middelburg Hospital on June 7 - 6/23/2011
Regional nodal irradiation improves breast CA survival
CHICAGO | All women with early breast cancer should be offered regional nodal irradiation (RNI) by their physicians to improve their long-term disease-free survival, according to Canadian-led research presented at the ASCO meeting here. - 6/23/2011
Adding bevacizumab to chemo improves ovarian cancer
CHICAGO | Two major ovarian cancer trials demonstrating the benefit of adding bevacizumab to traditional chemotherapy were presented at this year’s ASCO meeting. The first showed the angiogenesis blocker’s ability to extend progression-free survival in recurrent disease. The second suggested initial use of the tumour-starving drug for newly diagnosed cancer may be warranted, particularly in patients with more aggressive disease. - 6/23/2011
N.S. pharmacists and government reach tentative agreement
Details won’t be released until PANS shares information with members, final approvals are received. - 6/23/2011
National EMR certification push ‘too little, too late’: critic
Canada Health Infoway defends new certification program - 6/23/2011
Major breakthrough in untreated, unresectable advanced melanoma
CHICAGO | Truly groundbreaking change in the first-line treatment of metastatic melanoma has arrived for patients relegated to using the same largely ineffective regimens for many years. - 6/23/2011
CNA president says NP barriers cited by MDs no surprise
Other hurdles identified add up to a lack of clarity about role, value of NPs, adds Judith Shamian - 6/23/2011
Exemestane new option for breast cancer prevention in postmenopausal women
CHICAGO | The aromatase inhibitor exemestane reduces the risk of invasive breast cancer by 65% in high-risk postmenopausal women, according to a large phase III, placebo-controlled trial led and coordinated by Canada’s NCIC Clinical Trials Group.